JK 06
Alternative Names: JK-06; SAL-006Latest Information Update: 29 Jul 2026
At a glance
- Originator SalubrisBio
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2026 Efficacy and adverse events data from phase I/II trial in Solid tumors presented at 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 30 May 2026 Efficacy and adverse event data from phase I/II trial in Solid tumours released by SalubrisBio
- 22 Apr 2026 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research, 2026 (AACR-2026)